A meta-analysis comparing the effectiveness and safety of repetitive transcranial magnetic stimulation versus theta burst stimulation for treatment-resistant depression.

IF 3.2 3区医学 Q2 PSYCHIATRY

Frontiers in Psychiatry Pub Date : 2025-02-03 eCollection Date: 2024-01-01 DOI:10.3389/fpsyt.2024.1504727

Xiao Tao, Zheng Wen Jing, Wang Kui Yuan, Guo Hui Yun, Xie Jian Fang, Liao Ming Sheng

{"title":"A meta-analysis comparing the effectiveness and safety of repetitive transcranial magnetic stimulation versus theta burst stimulation for treatment-resistant depression.","authors":"Xiao Tao, Zheng Wen Jing, Wang Kui Yuan, Guo Hui Yun, Xie Jian Fang, Liao Ming Sheng","doi":"10.3389/fpsyt.2024.1504727","DOIUrl":null,"url":null,"abstract":"Objective: This study compares the safety and effectiveness of theta-burst stimulation (TBS) and repetitive transcranial magnetic stimulation (rTMS) for treating treatment-resistant depression (TRD).Methods: We reviewed randomized controlled trials (RCTs) that evaluated rTMS and TBS in managing TRD. Searches were conducted in PubMed, Embase, the Cochrane Library, and Web of Science for studies published up to July 31, 2024. Data from these studies were analyzed using statistical software.Results: Five RCTs involving 1,196 patients were included, with 553 receiving rTMS and 663 receiving TBS. The analysis found no significant differences between rTMS and TBS in reducing depression [SMD = -0.07, 95% CI (-0.19, 0.04)] or anxiety [SMD = -0.02, 95% CI (-0.15, 0.11)], nor in side effects like headaches [OR = 1.00, 95% CI (0.72, 1.40)], nausea [OR = 1.42, 95% CI (0.79, 2.54)], or fatigue [OR = 0.87, 95% CI (0.46, 1.64)].Conclusions: Both rTMS and TBS are similarly effective in reducing depression and anxiety symptoms, with comparable side effect profiles. However, TBS is more time-efficient, with sessions lasting only 192 seconds, making it a cost-effective option for patients. These findings support TBS as a practical treatment choice for TRD.","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"15 ","pages":"1504727"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841443/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fpsyt.2024.1504727","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study compares the safety and effectiveness of theta-burst stimulation (TBS) and repetitive transcranial magnetic stimulation (rTMS) for treating treatment-resistant depression (TRD).

Methods: We reviewed randomized controlled trials (RCTs) that evaluated rTMS and TBS in managing TRD. Searches were conducted in PubMed, Embase, the Cochrane Library, and Web of Science for studies published up to July 31, 2024. Data from these studies were analyzed using statistical software.

Results: Five RCTs involving 1,196 patients were included, with 553 receiving rTMS and 663 receiving TBS. The analysis found no significant differences between rTMS and TBS in reducing depression [SMD = -0.07, 95% CI (-0.19, 0.04)] or anxiety [SMD = -0.02, 95% CI (-0.15, 0.11)], nor in side effects like headaches [OR = 1.00, 95% CI (0.72, 1.40)], nausea [OR = 1.42, 95% CI (0.79, 2.54)], or fatigue [OR = 0.87, 95% CI (0.46, 1.64)].

Conclusions: Both rTMS and TBS are similarly effective in reducing depression and anxiety symptoms, with comparable side effect profiles. However, TBS is more time-efficient, with sessions lasting only 192 seconds, making it a cost-effective option for patients. These findings support TBS as a practical treatment choice for TRD.

查看原文本刊更多论文

研究目的本研究比较了θ-脉冲刺激（TBS）和重复经颅磁刺激（rTMS）治疗耐药抑郁症（TRD）的安全性和有效性：我们回顾了评估经颅磁刺激和经颅磁刺激治疗 TRD 的随机对照试验 (RCT)。我们在PubMed、Embase、Cochrane图书馆和Web of Science上搜索了截至2024年7月31日发表的研究。使用统计软件对这些研究的数据进行了分析：共纳入了五项研究，涉及 1196 名患者，其中 553 人接受了经颅磁刺激，663 人接受了经颅磁刺激。分析发现，经颅磁刺激疗法和经颅磁刺激疗法在减轻抑郁[SMD = -0.07，95% CI (-0.19, 0.04)]或焦虑[SMD = -0.02，95% CI (-0.15, 0.11)]方面无明显差异，在副作用方面也无明显差异。11）]，也没有头痛[OR = 1.00，95% CI（0.72，1.40）]、恶心[OR = 1.42，95% CI（0.79，2.54）]或疲劳[OR = 0.87，95% CI（0.46，1.64）]等副作用：经颅磁刺激疗法和经颅磁刺激疗法在减轻抑郁和焦虑症状方面的效果相似，副作用也相当。然而，经颅磁刺激疗法更省时，疗程仅需 192 秒，因此对患者来说是一种经济有效的选择。这些研究结果支持将 TBS 作为治疗 TRD 的实用选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Psychiatry Medicine-Psychiatry and Mental Health

CiteScore

6.20

自引率

8.50%

发文量

2813

审稿时长

14 weeks

期刊介绍： Frontiers in Psychiatry publishes rigorously peer-reviewed research across a wide spectrum of translational, basic and clinical research. Field Chief Editor Stefan Borgwardt at the University of Basel is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. The journal''s mission is to use translational approaches to improve therapeutic options for mental illness and consequently to improve patient treatment outcomes.